2021 Conference on Retroviruses and Opportunistic Infections*

Download All
March 6-10, 2021; Virtual
Learn about the latest HIV data with live Webinars, rapid Capsule Summaries, and downloadable slides, and get global perspectives from expert commentaries on key studies from the virtual 2021 CROI.

Highlights

Capsule Summary Slidesets

Phase IIa study demonstrates that novel maturation inhibitor exhibits dose-response antiviral activity, in vivo concentrations above clinical efficacy targets, and good tolerability.

Released: March 10, 2021

Racial and ethnic disparities are evident among PWH testing positive for COVID-19 in the United States.

Released: March 12, 2021

Both PrEP regimens were highly effective in preventing HIV infection in this open-label study.

Released: March 10, 2021

Longitudinal analysis of HIV infections, viral load, cabotegravir concentrations, and emergent resistance in HPTN 083 demonstrated the importance of prompt diagnosis and initiation of ART to avoid resistance in cases of breakthrough infection with long-acting cabotegravir as PrEP.

Released: March 10, 2021

Among South African women COVID-19 was associated with an increased maternal mortality rate in high-risk pregnancy but pregnancy and neonatal outcomes were generally similar with vs without HIV infection.

Released: March 12, 2021

Superior virologic efficacy observed with DTG-based regimen vs EFV-based regimen throughout pregnancy and through the breastfeeding period: final results of the DolPHIN-2 study.

Released: March 10, 2021

In this randomized noninferiority trial, the overall safety and efficacy of DTG plus FTC/TAF or FTC/TDF was generally similar to EFV/FTC/TDF when initiated during pregnancy, but in post hoc analyses, infant mortality, virologic failure at ≥ 24 weeks, and maternal weight loss were all higher with EFV/FTC/TDF vs DTG-based regimens.

Released: March 11, 2021

Long-acting cabotegravir plus rilpivirine injections every 2 months are noninferior to monthly injections at Week 96 in virologically suppressed patients with no prior virologic failure.

Released: March 11, 2021

Study finds that use of genotypic resistance testing to guide management of patients experiencing first-line ART failure does not improve viral suppression rates, highlighting need for alternative strategies to improve management of ART failure.

Released: March 8, 2021

Higher levels of immune activation biomarkers more strongly predict vascular events in virologically suppressed women with HIV compared with virologically suppressed men with HIV.

Released: March 12, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue